Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids

Abstract Ipilimumab is an anti-CTLA-4 antibody which has recently been approved in Europe as a monotherapy in the treatment of metastatic melanoma.We report a single-center study among patients treated within a Temporary Authorization for Use (TAU) protocol.We also performed a review of the literature involving expanded access program studies with a focus on factors associated with overall survival (OS).